| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Omnicorder Technologies, Inc. |
| 25 East Loop Road, Stony Brook, NY 11790 * (516) 444-6499 |
| The company is a development stage company incorporated in 1997 to engage in the business of providing innovative screening services and clinical information for the early detection and management of breast cancer and other diseases. |
| Manager | Tier | Phone |
| Cambridge Capital LLC | Lead Manager |
| NASSCM: | OCTI | Service: | SIC 8099 | |
| Type of Shares: | Common Shares | Filing Date: | 10/23/98 | |
| U.S. Shares Filed: | 1,100,000 | Filing Range: | $8.00 - $10.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $9,900,000 | |
| Primary Shares: | 1,100,000 | Expenses: | - | |
| Secondary Shares: | 0 | Post-IPO Shares: | ||
| Employees: | 8 |
| Issuer's Law Firm: | Meltzer, Lippe, Goldstein, Wolf, Schlissel & Sazer |
| Bank's Law Firm: | Whitman Breed Abbott & Morgan LLP |
| Registrar/Transfer Agent: | Continental Stock Transfer & Trust Co |
| Auditor: | Pricewaterhouse Coopers LLC |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 9/30/98 | 9/30/97 | 9/30/98 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $1.00 |
| Net Income: | -$0.14 | -$0.74 | -$0.08 | Curr Assets: | $0.74 |
| EPS: | -$0.09 | -$0.35 | -$0.04 | Liabilities: | $0.30 |
| Prior EPS: | Curr Liab: | $0.13 | |||
| Cash Flow/Oper: | -$0.11 | -$0.53 | $0.02 | Equity: | $0.70 |
| Cash Flow/Fin: | $0.19 | $0.99 | -$0.02 | Cash: | $0.48 |
| Cash Flow/Inv: | $0.00 | $0.06 | Working Cap: | $0.61 | |
| Competition |
| The Company is not aware of any devices currently on the market which will be capable of competing directly with the DAT System, although several new companies are developing technologies aimed at the same market niche as DAT, and there may be others of which the Company is unaware. The Company's potential competitors may succeed in developing products that are more effective or less costly (or both) than the Company's products, and such competitors may also prove to be more successful than the Company in manufacturing, marketing, and sales. Some of the Company's potential competitors may be large, well-financed and established companies that have greater resources than the Company, and, therefore, may be better able than the Company to compete for a share of the market even in areas in which the Company may have superior technology. The Company also competes with existing diagnostic lternatives, most notably x-ray mammography. Significant barriers to the Company's success are posed by these existing alternatives. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund research and development, repayment of bridge notes, purchase of capital equipment, working capital and for general corporate purposes. |
| Additional Underwriter Compensation |
| Warrant to purchase 110,000 shares/units at a nominal price. |
| $30,000.00 consulting agreement for 2 year(s). |